Actinium Pharmaceuticals, Inc.
ATNM evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ATNM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ATNM
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapies for cancer, including its lead candidate Iomab-B and a pipeline of preclinical assets for solid tumors.
Key risk: Clinical and regulatory risks
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 3 clinical trials for Actinium Pharmaceuticals, Inc..
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapies for cancer, including its lead candidate Iomab-B and a pipeline of preclinical assets for solid tumors.
- Cash and equivalents of $36.8M as of 2026-06-30 [sec].
- Total revenue of $35.0M and net income of $27.9M for the six months ended 2026-06-30 [sec].
- Intellectual property portfolio comprises approximately 250 patents and patent applications across multiple jurisdictions [sec_mda · as of 2026-05-08].
- Partnership with Immedica Pharma AB to commercialize Iomab-B in the EUMENA region provided a $35 million upfront payment and potential milestone payments up to $452 million [sec · filed 2022-11-21].
- Presented first preclinical data for ATNM-400, a novel non-PSMA Ac-225 targeted radiotherapy, at AACR in April 2025 [sec_mda · as of 2025-08-08].
What works
- Strong cash position of $36.8M as of 2026-06-30, with revenue of $35.0M and net income of $27.9M, indicating recent financial improvement [sec].
- Extensive intellectual property portfolio of approximately 250 patents and patent applications provides a competitive moat [sec_mda · as of 2026-05-08].
- Partnership with Immedica Pharma for Iomab-B in EUMENA includes a $35M upfront payment and potential milestone payments up to $452M, validating commercial potential [sec · filed 2022-11-21].
- Pipeline includes novel targeted radiotherapeutics for solid tumors, such as ATNM-400, with preclinical data presented at AACR 2025 [sec_mda · as of 2025-08-08].
What to weigh
- The company faces risks common to biopharmaceutical firms, including completing clinical trials, obtaining regulatory approvals, and securing additional capital [sec_mda · as of 2026-08-07].
- Geopolitical conflicts and macroeconomic conditions, such as the Russia-Ukraine war and Middle East conflicts, could adversely affect the business [sec_mda · as of 2026-08-07].
- The company will require additional funds to conduct clinical trials and achieve regulatory approvals, with no guarantee of future financing [sec_mda · as of 2025-03-31].
- Dependence on key personnel and protection of proprietary technology are ongoing challenges [sec_mda · as of 2026-08-07].
From the filings
Quoted directly from source documents.
Intellectual property portfolio comprises approximately 250 patents and patent applications
“Our intellectual property portfolio comprises approximately 250 patents and patent applications across multiple jurisdictions.”
SEC MD&A · May 8, 2026
Partnership with Immedica Pharma provided a $35 million upfront payment
“Our partnership with Immedica Pharma AB to commercialize Iomab -B in the EUMENA region provided a $35 million payment upfront”
SEC filings · November 21, 2022
Risks & what to watch (4)›
Key risks
- Clinical and regulatory risks — Risks associated with completing preclinical studies and clinical trials, and receiving regulatory approvals for product candidates [sec_mda · as of 2026-08-07].
- Need for additional capital — The company will require additional funds to conduct trials and achieve regulatory approvals, with no assurance of future financing [sec_mda · as of 2025-03-31].
- Geopolitical and macroeconomic impact — Geopolitical conflicts and global inflation could adversely affect the business and market conditions [sec_mda · as of 2026-08-07].
- Dependence on key personnel and IP — Dependence on key personnel and protection of proprietary technology are critical to success [sec_mda · as of 2026-08-07].
What to watch
- Progress of Iomab-B commercialization in the EUMENA region through the Immedica partnership [sec · filed 2022-11-21].
- Advancement of preclinical solid tumor programs, including ATNM-400, into IND-enabling studies [sec_mda · as of 2025-08-08].
- Ability to secure additional financing to support ongoing operations and clinical trials [sec_mda · as of 2025-03-31].
- Updates on the company's intellectual property portfolio and patent filings [sec_mda · as of 2026-05-08].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Actinium Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Actinium Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
21.5 months
D/E 0.33 · 0% dilution
Lead: Phase 2/Phase 3
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
55
Total value held
$6.0M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 2,511,032 | $2.5M |
| millennium management llc | 564,600 | $562K |
| renaissance technologies llc | 471,600 | $469K |
| blackrock, inc. | 371,210 | $369K |
| two sigma investments, lp | 337,168 | $336K |
| geode capital management, llc | 336,073 | $335K |
| gagnon securities llc | 201,300 | $200K |
| vanguard fiduciary trust co | 160,265 | $159K |
| state street corp | 126,215 | $126K |
| susquehanna international group, llp | 123,998 | $123K |
Showing top 10 of 55 institutional holders of Actinium Pharmaceuticals, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 3.4%
- Days to cover
- 3.9
- Shares short
- 1,059,722
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ATNM short interestGovernance
Frequently asked questions
What is the AI investment thesis for Actinium Pharmaceuticals, Inc.?
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapies for cancer, including its lead candidate Iomab-B and a pipeline of preclinical assets for solid tumors.
What is Actinium Pharmaceuticals, Inc.'s lead drug candidate?
Actinium Pharmaceuticals, Inc.'s most advanced tracked candidate is Actimab-A (Phase 2/Phase 3) for Acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and solid tumors (HNSCC, NSCLC, GBM, MSI-high colorectal cancer).
Who is the CEO of Actinium Pharmaceuticals, Inc.?
Mr. Sandesh C. Seth M.B.A., M.S. is the chief executive officer of Actinium Pharmaceuticals, Inc. (ATNM).
Where is Actinium Pharmaceuticals, Inc. headquartered?
Actinium Pharmaceuticals, Inc. (ATNM) is headquartered in New York, NY, United States.
What therapeutic areas does Actinium Pharmaceuticals, Inc. focus on?
Actinium Pharmaceuticals, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.